Ligand Pharmaceuticals LGND Payments For Derivative Instrument Investing Activities
Payments For Derivative Instrument Investing Activities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForDerivativeInstrumentInvestingActivities.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's payments for derivative instrument investing activities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's payments for derivative instrument investing activities?
- Ligand Pharmaceuticals (LGND) reported payments for derivative instrument investing activities of $0 in Q1 2026.
- How has Ligand Pharmaceuticals's payments for derivative instrument investing activities changed year-over-year?
- Ligand Pharmaceuticals's payments for derivative instrument investing activities decreased by 100.0% year-over-year, from $7.62M to $0.
- What does payments for derivative instrument investing activities mean?
- Cash outflows related to the purchase or settlement of derivative financial instruments held for investment purposes. These instruments are typically used to hedge market risks or gain exposure to specific financial assets. Monitoring these payments helps investors understand the company's risk management activities and speculative investment strategies.